I-Mab (NASDAQ:NBP) Posts Quarterly Earnings Results

I-Mab (NASDAQ:NBP) announced its quarterly earnings data on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, FiscalAI reports.

I-Mab Stock Performance

Shares of NBP opened at $2.45 on Thursday. I-Mab has a one year low of $0.62 and a one year high of $6.79. The stock has a 50-day moving average price of $3.00. The firm has a market capitalization of $282.46 million, a PE ratio of -6.81 and a beta of 1.74.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new position in I-Mab (NASDAQ:NBP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 12,715 shares of the company’s stock, valued at approximately $51,000. Institutional investors and hedge funds own 38.38% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Wall Street Zen cut shares of I-Mab from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of I-Mab in a research note on Wednesday. Finally, Weiss Ratings assumed coverage on shares of I-Mab in a research note on Thursday, February 5th. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, I-Mab presently has an average rating of “Hold” and a consensus target price of $9.00.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.